Viewing StudyNCT00272987



Ignite Creation Date: 2024-05-05 @ 4:37 PM
Last Modification Date: 2024-10-26 @ 9:22 AM
Study NCT ID: NCT00272987
Status: TERMINATED
Last Update Posted: 2023-04-28
First Post: 2006-01-04

Brief Title: ErbB2 Over-expressing Metastatic Breast Cancer Study Using Paclitaxel Trastuzumab and Lapatinib
Sponsor: Novartis Pharmaceuticals
Organization: Novartis

Conditions & Keywords Data

Conditions:
Name
Neoplasms Breast
Keywords:
Name View
lapatinib View
trastuzumab View
ErbB2 View
paclitaxel View
Herceptin View
Taxol View
ErbB1 View
metastatic breast cancer View
Stage IV breast cancer View